Back
Mineralys Therapeutics Stock Predictions
Why Private Investors Didn't Lose a Penny in the Market's Recent $1T Crash
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
70
MLYS
Mineralys Therapeutics
Last Price:
$16.87
Seasonality Move:
-0.62%
7 Day Trial
ALL ACCESS PASS
$
7
Apple just traded your privacy for $20 Billion
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.Mineralys Therapeutics Stock Forecast
-
Over the next 52 weeks, Mineralys Therapeutics has on average historically risen by 7.2% based on the past 2 years of stock performance.
-
Mineralys Therapeutics has risen higher in 1 of those 2 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
-
Is Mineralys Therapeutics Stock Undervalued?The current Mineralys Therapeutics [MLYS] share price is $16.87. The Score for MLYS is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.
-
MLYS is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
Will Mineralys Therapeutics Stock Go Up Next Year?
-
Over the next 52 weeks, Mineralys Therapeutics has on average historically risen by 7.2% based on the past 2 years of stock performance.
Mineralys Therapeutics Stock Rating
Buy
70
Mineralys Therapeutics (MLYS)
is a Buy
Is Mineralys Therapeutics overpriced?
-
Mineralys Therapeutics has risen higher in 1 of those 2 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Mineralys Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
mineralystx.com
52-Week Data
52-Week High:
18.38
52-Week Low:
8.24
Prediction Charts
Market Cap:
1.1B
Price in USD:
16.87
Volume:
832.4K
Beta:
1.47
Technical Analysis
SMA50:
10.93
SMA100:
11.91
SMA200:
12.16
52-Wk Change:
28.88%
Stock Predictions
-
Is Mineralys Therapeutics stock public?Yes, Mineralys Therapeutics is a publicly traded company.
-
What is the Mineralys Therapeutics stock quote today?The Mineralys Therapeutics stock price is 16.87 USD today.
-
How to buy Mineralys Therapeutics stock online?You can buy Mineralys Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Mar-3 | 9.17 | 8.94 | 9.44 | 8.69 |
| Mar-4 | 8.85 | 9.93 | 10.00 | 8.79 |
| Mar-5 | 10.00 | 10.01 | 10.33 | 9.80 |
| Mar-6 | 9.86 | 10.54 | 10.82 | 9.69 |
| Mar-7 | 10.57 | 10.52 | 10.77 | 10.19 |
| Mar-11 | 15.30 | 14.30 | 15.98 | 13.41 |
| Mar-12 | 12.59 | 13.11 | 13.57 | 12.55 |
| Mar-13 | 13.03 | 13.50 | 13.95 | 12.77 |
| Mar-14 | 13.87 | 14.25 | 14.40 | 13.53 |
| Mar-17 | 14.28 | 14.22 | 14.46 | 13.80 |
| Mar-18 | 14.46 | 15.43 | 15.50 | 14.31 |
| Mar-19 | 15.47 | 16.75 | 18.38 | 15.23 |
| Mar-20 | 16.43 | 16.73 | 17.29 | 16.32 |
| Mar-21 | 16.60 | 16.87 | 17.26 | 16.56 |
Mineralys Therapeutics Earnings
Mineralys Therapeutics Earnings Report: Per Share Mineralys Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.
Mineralys Therapeutics Forecast Revenue Growth
Mineralys Therapeutics Stock Analysis: Historical quarterly revenues per share for Mineralys Therapeutics and historical quarterly revenue growth:
-
Analysts estimate an earnings decrease this quarter of $0.07 per share, an increase next quarter of $0.09 per share, a decrease this year of $0.18 per share, and a decrease next year of $0.07 per share.
* Mineralys Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.